Nurix Therapeutics (NRIX) EBT Margin (2019 - 2025)
Historic EBT Margin for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to 576.13%.
- Nurix Therapeutics' EBT Margin fell 1354400.0% to 576.13% in Q4 2025 from the same period last year, while for Nov 2025 it was 314.0%, marking a year-over-year increase of 403600.0%. This contributed to the annual value of 314.0% for FY2025, which is 403600.0% up from last year.
- Latest data reveals that Nurix Therapeutics reported EBT Margin of 576.13% as of Q4 2025, which was down 1354400.0% from 1094.77% recorded in Q3 2025.
- Over the past 5 years, Nurix Therapeutics' EBT Margin peaked at 79.14% during Q2 2023, and registered a low of 1094.77% during Q3 2025.
- In the last 5 years, Nurix Therapeutics' EBT Margin had a median value of 379.17% in 2024 and averaged 399.66%.
- Per our database at Business Quant, Nurix Therapeutics' EBT Margin surged by 4119600bps in 2023 and then crashed by -7065100bps in 2025.
- Over the past 5 years, Nurix Therapeutics' EBT Margin (Quarter) stood at 509.17% in 2021, then crashed by -35bps to 688.74% in 2022, then skyrocketed by 60bps to 276.77% in 2023, then crashed by -59bps to 440.69% in 2024, then crashed by -31bps to 576.13% in 2025.
- Its EBT Margin was 576.13% in Q4 2025, compared to 1094.77% in Q3 2025 and 96.93% in Q2 2025.